Bio-Bridge Science Dedicated to Developing a Vaccine to Fight HIV
December 01 2006 - 1:16PM
Business Wire
According to a joint report issued by UNAIDS and WHO, an estimated
39.5 million people globally are living with HIV and an estimated
4.3 million individuals were newly infected during 2006. An
overwhelming proportion of the people living with HIV are in
Sub-Saharan Africa where the estimated number of people infected is
24.7 million. The number of people estimated to be living with HIV
is 1.2 million in the U.S., 650,000 in China, and 17,000 in Japan.
China's Ministry of Health expressed recently that the number of
people officially reported as infected by HIV has risen 27.5
percent since the beginning of 2006 according to Xinhua. To curb
the global spread of HIV, experts believe that a vaccine is needed
to fight HIV infection. Bio-Bridge Science, Inc. (OTCBB: BGES) is
in development of a promising new HIV Vaccine that is expected to
enter clinical trials in 2007 in China. The vaccine targets
infection in mucosal tissues, which is a unique approach to prevent
and treat HIV infection. The pre-clinical trials have been done in
China and suggest that the vaccine is safe and effective in the
treatment and prevention of HIV.�Bio-Bridge is dedicated to
developing this HIV therapeutic and preventive vaccine to fight
HIV/AIDS. Links:
http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf
http://news3.xinhuanet.com/english/2006-11/30/content_5414604_1.htm
Forward Looking Statements: This press release contains
forward-looking statements as defined by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future
events or performance, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to SEC filings for additional information.
According to a joint report issued by UNAIDS and WHO, an estimated
39.5 million people globally are living with HIV and an estimated
4.3 million individuals were newly infected during 2006. An
overwhelming proportion of the people living with HIV are in
Sub-Saharan Africa where the estimated number of people infected is
24.7 million. The number of people estimated to be living with HIV
is 1.2 million in the U.S., 650,000 in China, and 17,000 in Japan.
China's Ministry of Health expressed recently that the number of
people officially reported as infected by HIV has risen 27.5
percent since the beginning of 2006 according to Xinhua. To curb
the global spread of HIV, experts believe that a vaccine is needed
to fight HIV infection. Bio-Bridge Science, Inc. (OTCBB: BGES) is
in development of a promising new HIV Vaccine that is expected to
enter clinical trials in 2007 in China. The vaccine targets
infection in mucosal tissues, which is a unique approach to prevent
and treat HIV infection. The pre-clinical trials have been done in
China and suggest that the vaccine is safe and effective in the
treatment and prevention of HIV. Bio-Bridge is dedicated to
developing this HIV therapeutic and preventive vaccine to fight
HIV/AIDS. Links:
http://data.unaids.org/pub/EpiReport/2006/2006_EpiUpdate_en.pdf
http://news3.xinhuanet.com/english/2006-11/30/content_5414604_1.htm
Forward Looking Statements: This press release contains
forward-looking statements as defined by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements include
statements concerning plans, objectives, goals, strategies, future
events or performance, and underlying assumptions and other
statements that are other than statements of historical facts.
These statements are subject to uncertainties and risks including,
but not limited to, product and service demand and acceptance,
changes in technology, economic conditions, the impact of
competition and pricing, government regulation, and other risks
defined in this document and in statements filed from time to time
with the Securities and Exchange Commission. All such
forward-looking statements, whether written or oral, and whether
made by or on behalf of the company, are expressly qualified by
these cautionary statements and any other cautionary statements
which may accompany the forward-looking statements. In addition,
the company disclaims any obligation to update any forward-looking
statements to reflect events or circumstances after the date
hereof. Please refer to SEC filings for additional information.
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bio Bridge Science (CE) (USOTC:BGES)
Historical Stock Chart
From Jul 2023 to Jul 2024